newsfilter
← Latest News
GlobeNewswire·

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET - PHILADELPHIA an